BRIEF: Teva, Perrigo get FDA nod for allergy nasal spray: Teva will market generic Nasacort, which Perrigo will manufacture unde
TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA | Quote | Chart | News | PowerRating) and Perrigo Company (Nasdaq:PRGO; TASE: PRGO | Quote | Chart | News | PowerRating) announced that they obtained US Food and Drug Administration (FDA) marketing approval for generic Nasacort (Triamcinolone Acetonide) nasal spray for allergies. Perrigo developed the product and Teva unit Barr Pharmaceuticals was the first to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification with the FDA.
Teva will market generic Nasacort, which Perrigo will manufacture under license from Sanofi-Aventis SA (NYSE: SNY; Euronext: SAN) beginning in June 2011. Perrigo will share in the costs and benefits in Teva's marketing of the product.
Brand Nasacort has annual US sales of $305 million, according to Wolters Kluwer data.
Teva's share closed at $53.58 on Nasdaq yesterday, and rose 0.4 percent in early trading on the TASE today to NIS 202.50. Perrigo's share closed at $28.03 on Nasdaq yesterday, and was unchanged on the TASE at NIS 106.60.
To see more of the Globes or to subscribe to the newspaper, go to
http://www.globes-online.com. Copyright (c) 2009, Globes, Tel Aviv, Israel
Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.
For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.
For full details on Perrigo Co (PRGO) PRGO. Perrigo Co (PRGO) has Short Term PowerRatings at TradingMarkets. Details on Perrigo Co (PRGO) Short Term PowerRatings is available at This Link.
- Israeli Teva gets rights for multiple sclerosis drug in Nordic, Baltic states - 02/09/10
- Teva Pharmaceutical Industries: The Trend Continues Higher (TEVA) - 02/09/10
- BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI) - 02/09/10
- Teva and Active Biotech amend marketing and distribution agreement - 02/09/10
- FDA Accepts Teva's XM02 for Neutropenia - 02/09/10
- More News >>


